Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.57 |
| ▸ | HTR3B | O95264 | 3/20 | 0.57 |
| ▸ | HTR3A | P46098 | 3/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.51 |
| ▸ | BPTF | Q12830 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31357639 | 0.98 | HRH3 (0.63) | HRH3HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL21815362 | 0.98 | HRH3 (0.63) | HRH3HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3949154 | 0.83 | TRPV1 (0.51) | HRH3HRH4CYP1A2TRPV1 | |
| SCHEMBL29519276 | 0.83 | TRPV1 (0.51) | HRH3HRH4CYP1A2TRPV1 | |
| SCHEMBL1427479 | 0.83 | TRPV1 (0.51) | HRH3HRH4TRPV1 | |
| SCHEMBL1088796 | 0.81 | CXCR4 (0.51) | HRH3HRH4CYP1A2TRPV1 | |
| SCHEMBL2087838 | 0.81 | CXCR4 (0.51) | HRH3HRH4CYP1A2TRPV1 | |
| SCHEMBL28219653 | 0.80 | TRPV1 (0.49) | HRH3HRH4TRPV1 | |
| SCHEMBL10970453 | 0.79 | HRH3 (0.61) | HRH3HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL20991838 | 0.79 | CCNT1 (0.48) | HRH3KDM4ETRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856737-B1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-05-17 | — | — | EP | disclosed |
| US-20210395239-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395239-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3856737-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-08-04 | — | — | EP | disclosed |
| CN-112752755-A | Heterocyclyl compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-05-04 | — | — | CN | disclosed |
| WO-2020064792-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-04-02 | — | — | WO | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| EP-3355699-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | OncoTherapy Science, Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| CN-100451016-C | Piperazinylpyrazine compounds as agonists or antagonists of serotonin 5ht-2 receptors | BIOVITRUM AB (SE) | 2009-01-14 | — | — | CN | disclosed |
| CN-1267424-C | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | BIOVITRUM AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| CN-1479727-A | Piperazinylpyrazine compounds as agonists or antagonists of the 5-hydroxytryptamine 5 HT-2 receptor | �Ȱ�ά����ķ�ɷݹ�˾ | 2004-03-03 | — | — | CN | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
| EP-0714896-A1 | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF MIGRAINE, COMPOSITION AND UTILIZATION | VITA-INVEST, S.A. (ES) | 1996-06-05 | — | — | EP | disclosed |
| EP-0063509-B1 | 2-PIPERAZINO-PYRIMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM AND THEIR USE AS INTERMEDIATES IN THE MANUFACTURE OF MEDICAMENTS | PHARMUKA LABORATOIRES (FR) | 1985-02-20 | — | — | EP | disclosed |
| EP-0063509-A1 | 2-Piperazino-pyrimidine derivatives, processes for their preparation, medicaments containing them and their use as intermediates in the manufacture of medicaments | PHARMUKA LABORATOIRES (FR) | 1982-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395239-A1 | HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, HLA-DRB1, UACA | HRH3 36/4885HTR3E 4486/4885HTR3B 3635/4885 |
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | HRH3 2101/4885HTR3E 2506/4885HTR3B 1922/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | HRH3 2101/4885HTR3E 2506/4885HTR3B 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.